Salsalate: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: In pharmacology, '''salsalate''', also called '''salicylsalicylic acid''' and '''disalicylic acid''', is a medication which is a non-steroidal anti-inflammatory agent. Salsala...) |
imported>Robert Badgett No edit summary |
||
| Line 1: | Line 1: | ||
In [[pharmacology]], '''salsalate''', also called '''salicylsalicylic acid''' and '''disalicylic acid''', is a [[medication]] which is a [[non-steroidal anti-inflammatory agent]]. | In [[pharmacology]], '''salsalate''', also called '''salicylsalicylic acid''' and '''disalicylic acid''', is a [[medication]] which is a [[non-steroidal anti-inflammatory agent]]. Salsalate is related to acetylsalicylic acid ([[aspirin]]), but unlike acetylsalicylic acid, salsalate does not irreversibly inhibit [[cyclooxygenase]] and thus is not an [[anti-platelet agent]]. | ||
Salsalate may reduce the [[Glycosylated hemoglobin A|Glycosylated hemoglobin A1c]] in patients with [[diabetes mellitus type 2]].<ref name="pmid20231565">{{cite journal| author=Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE et al.| title=The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. | journal=Ann Intern Med | year= 2010 | volume= 152 | issue= 6 | pages= 346-57 | pmid=20231565 | doi=10.1059/0003-4819-152-6-201003160-00004 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20231565 }} </ref> | Salsalate may reduce the [[Glycosylated hemoglobin A|Glycosylated hemoglobin A1c]] in patients with [[diabetes mellitus type 2]].<ref name="pmid20231565">{{cite journal| author=Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE et al.| title=The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. | journal=Ann Intern Med | year= 2010 | volume= 152 | issue= 6 | pages= 346-57 | pmid=20231565 | doi=10.1059/0003-4819-152-6-201003160-00004 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20231565 }} </ref> | ||
==Drug toxicity== | |||
Tinnitus may happen, but is unlikely if the total daily dose is 3 grams or less.<ref name="pmid20231565">{{cite journal| author=Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE et al.| title=The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. | journal=Ann Intern Med | year= 2010 | volume= 152 | issue= 6 | pages= 346-57 | pmid=20231565 | doi=10.1059/0003-4819-152-6-201003160-00004 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20231565 }} </ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 00:45, 6 January 2011
In pharmacology, salsalate, also called salicylsalicylic acid and disalicylic acid, is a medication which is a non-steroidal anti-inflammatory agent. Salsalate is related to acetylsalicylic acid (aspirin), but unlike acetylsalicylic acid, salsalate does not irreversibly inhibit cyclooxygenase and thus is not an anti-platelet agent.
Salsalate may reduce the Glycosylated hemoglobin A1c in patients with diabetes mellitus type 2.[1]
Drug toxicity
Tinnitus may happen, but is unlikely if the total daily dose is 3 grams or less.[1]
References
- ↑ 1.0 1.1 Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE et al. (2010). "The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.". Ann Intern Med 152 (6): 346-57. DOI:10.1059/0003-4819-152-6-201003160-00004. PMID 20231565. Research Blogging.
Cite error: Invalid
<ref>tag; name "pmid20231565" defined multiple times with different content